National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Siponimod (Mayzent®) HTA ID: 19053

Siponimod (Mayzent®) is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

NCPE Assessment Process Ongoing
Rapid review commissioned 03/12/2019
Rapid review completed 13/01/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of siponimod compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 27/01/2020
Pre-submission consultation with Applicant 02/03/2020
Submission received from Applicant 20/05/2020
Preliminary review sent to Applicant 17/09/2020
Current status Awaiting response from Applicant